European Patent on Ascend Advanced Therapies’ EpyQ® AAV Plasmid Technology Successfully Defended at the EPO

Rockville, Maryland – 8th October, 2025 – Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, protecting EpyQ®, the company’s proprietary AAV plasmid technology, has been successfully defended in opposition proceedings before the European Patent Office (EPO). This outcome confirms the novelty and robustness of Ascend’s pioneering approach to AAV plasmid design Read More The post European Patent on Ascend Advanced Therapies’ EpyQ® AAV Plasmid Technology Successfully Defended at the EPO appeared first on Ascend .